Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“weight gain was also significantly higher in the treatment group [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“a randomized controlled trial including 101 patients with either pre‐ or type 2 diabetes found that 51% in the Pioglitazone group (45 mg/day) had resolution of NASH and 58% achieved the primary outcome of the study (reduction of ≥2 NAS points in two histologic categories without worsening of fibrosis), both significantly [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“Pioglitazone treatment was also associated with a significant improvement in fibrosis score.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“5) mg/dL 149 (36) 153 (34) 1 (−18 to 19) LDL cholesterol level 0.”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 3×
“Additional secondary outcomes included the following: 1) fasting plasma glucose, fasting plasma insulin, FFA, hemoglobin A1c, fasting plasma lipid profile, adiponectin, and cytokeratin-18 concentrations; 2) total body fat percentage, measured by DXA; 3) hepatic triglyceride content, measured by magnetic resonance and…”
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“001 Fibrosis ≥1-point improvement, n (%) 13 (25) 20 (39) 14 (−6 to 34) 0.”
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Research works printed but not linked: 1
- Bril F, 2015, Diabetes, 64, A337
Cited by
Items 401–500 of 1,001
Jayashankar, V., Selwan, E. M., Hancock, S. E., Verlande, A., Goodson, M. O., Eckenstein, K. H., Milinkeviciute, G., Hoover, B., Chen, B., Fleischman, A. G., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013086 · Cited by 33
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
Sun, L., Deng, C., Gu, Y., He, Y., Yang, L., & Shi, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101876 · Cited by 35
Muthiah, M. D., Ng, C. H., Xiao, J., Chin, Y. H., Lim, G., Lim, W. H., Tay, P. W. L., Tan, D. J. H., Yong, J. N., Pan, X., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16808 · Cited by 32
Davidson, M. B., & Pan, D. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.002 · Cited by 37
Giampietro, L., Laghezza, A., Cerchia, C., Florio, R., Recinella, L., Capone, F., Ammazzalorso, A., Bruno, I., Filippis, B. D., Fantacuzzi, M., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00574 · Cited by 34
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Dong, Q., Bao, H., Wang, J., Shi, W., Zou, X., Sheng, J., Gao, J., Guan, C., Xia, H., Li, J., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1120621 · Cited by 35
Dai, J.-J., Zhang, Y., & Zhang, Z. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i37.5339 · Cited by 36
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 61
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
Thiagarajan, P., & Aithal, G. P. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.03.002 · Cited by 33
Stratification of patients in NASH clinical trials: A pitfall for trial success
Ampuero, J., & Romero-Gomez, M. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100148 · Cited by 30
“enrolled 50 patients taking the same drug for 72 weeks.(15) Regarding baseline features, themain difference between these trials was that Sanyal et al.”
BackgroundNonalcoholic Fatty Liver Disease
Seth, A., & Balakrishnan, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48662-8_5 · Cited by 31
COSMIC project: consensus on the objectives of the metabolic syndrome in clinic
Pedro‐Botet, J., Ascaso, J. F., Barrios, V., de la Sierra, A., Escalada, J., Millán, J., Mostaza, J. M., Pérez‐Martínez, P., Pintó, X., Salas‐Salvadó, J., et al. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s165740 · Cited by 33
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
“An initial study detected a reduction in liver enzymes in NASH patients, with an improvement in histological parameters and a reduction in liver lipids and plasma triglycerides [195,196], and subsequent trials confirmed these data in NAFLD and type 2 diabetes patients [197,198] and in NASH subjects [199].”
ResultLian, J., & Fu, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649018 · Cited by 30
NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics
Kounatidis, D. C., Vallianou, N. G., Geladari, E. V., Panoilia, M.-P., Daskou, A., Stratigou, T., Karampela, Ι., Tsilingiris, D., & Dalamaga, Μ. (2024) · Biomedicines · doi:10.3390/biomedicines12040826 · Cited by 40
“NAS has been widely adopted in landmark studies to evaluate the therapeutic potential of vitamin E and pioglitazone among patients with NASH [42–44].”
MethodThe pharmacological management of NAFLD in children and adolescents
Liyanagedera, S., Williams, R. P., Veraldi, S., Nobili, V., & Mann, J. P. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1365599 · Cited by 32
Wong, T., Wong, R. J., & Gish, R. G. (2019) · Europe PMC (PubMed Central) · Cited by 35
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Cernea, S. (2024) · Life · doi:10.3390/life14020272 · Cited by 36
“…SGLT 2: sodium–glucose cotransporter 2; N/A: not available; wk: week; THR: thyroid hormone receptor; SCD1: stearoyl-CoA desaturase; BID: twice a day; FGF: fibroblast growth factor; HFF: hepatic fat fraction; ELF: enhanced liver fibrosis; [] is presented as 95% confidence interval) [158,177–186].”
BackgroundNAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials
Khare, T., Liu, K., Chilambe, L. O., & Khare, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010306 · Cited by 34
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 35
Patel, P., Muller, C., & Paul, S. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.506 · Cited by 28
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
Jeong, S. W. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0115 · Cited by 31
“Pioglitazone causes weight gain [12-14], and its usefulness for NASH is still under investigation.”
BackgroundSaroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients
Padole, P., Arora, A., Sharma, P., Chand, P., Verma, N., & Kumar, A. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.015 · Cited by 32
Luo, Q., Wei, R., Cai, Y., Zhao, Q., Liu, Y., & Liu, W. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.793203 · Cited by 28
Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome
Wang, D., & He, B. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s362424 · Cited by 28
Concentration‐dependent response to pioglitazone in nonalcoholic steatohepatitis
Kawaguchi‐Suzuki, M., Bril, F., Kalavalapalli, S., Cusi, K. J., & Frye, R. F. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14111 · Cited by 28
Self-citationTreatment options for nonalcoholic steatohepatitis - a safety evaluation
Issa, D., Wattacheril, J. J., & Sanyal, A. J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1343299 · Cited by 30
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Kanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
Self-citationCurrent and Emerging Therapies for Non-alcoholic Fatty Liver Disease
Patel, S. S., & Siddiqui, M. S. (2018) · Drugs · doi:10.1007/s40265-018-1040-1 · Cited by 29
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
Roskilly, A., Hicks, A., Taylor, E., Jones, R. L., Parker, R., & Rowe, I. A. C. (2020) · Liver International · doi:10.1111/liv.14749 · Cited by 29
Bae, J. C., Beste, L. A., & Utzschneider, K. M. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1434 · Cited by 27
Pοlyzos, S. A., Bugianesi, E., Kountouras, J., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.001 · Cited by 30
“8 NAFLD activity score (NAS) in 2 histologic categories, without worsening of fibrosis [21].”
BackgroundMethodInfluentialPioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · Hepatology · doi:10.1002/hep.28960 · Cited by 26
Emerging targets for therapy in ALD: Lessons from NASH
Singal, A. K., Shah, V. H., & Malhi, H. (2023) · Hepatology · doi:10.1097/hep.0000000000000381 · Cited by 28
Godoy‐Matos, A. F., Valério, C. M., Júnior, W. S. D. S., Neto, J. M. D. A., & Bertoluci, M. C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01259-2 · Cited by 34
Kaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 34
Konings, L. A. M., Matute, L. M., Boeren, A. M. P., van de Luitgaarden, I. A. T., Dirksmeier-Harinck, F., de Knegt, R. J., Tushuizen, M. E., Grobbee, D. E., Holleboom, A. G., & Cabezas, M. C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70003 · Cited by 34
Jain, P., Jain, A., Deshmukh, R., Samal, P. K., Satapathy, T., & Ajazuddin, M. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102584 · Cited by 32
Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
Kalogirou, M., & Sinakos, E. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i11.790 · Cited by 27
Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment
Chen, M., Cai, J., Yu, Y., She, Z., & Li, H. (2019) · Gene Expression · doi:10.3727/105221619x15536120524171 · Cited by 27
Management of nonalcoholic fatty liver disease in the Middle East
Sanai, F. M., Abaalkhail, F. A., Hasan, F. A., Farooqi, M. H., Alnahdi, N., & Younossi, Z. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i25.3528 · Cited by 29
Grattagliano, I., Ciaula, A. D., Baj, J., Molina‐Molina, E., Shanmugam, H., Garruti, G., Wang, D. Q. ‐., & Portincasa, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1433-4_12 · Cited by 30
Non-alcoholic fatty liver disease: Current therapeutic options
Majumdar, A., Verbeek, J., & Tsochatzis, E. A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.007 · Cited by 28
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
At the Crossroads of Health and Disease: Consequences of Fat in the Liver
Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 38
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
Alkhouri, N., Tincopa, M. A., Loomba, R. S., & Harrison, S. A. (2021) · Hepatology Communications · doi:10.1002/hep4.1814 · Cited by 31
Tamura, Y. O., Sugama, J., Iwasaki, S., Sasaki, M., Yasuno, H., Aoyama, K., Watanabe, M., Erion, D. M., & Yashiro, H. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000786 · Cited by 29
Pennisi, G., Celsa, C., Spatola, F., Dallio, M., Federico, A., & Petta, S. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16224334 · Cited by 33
“Thiazolidinediones - Modulate adipose tissue distribution, decreasing visceral fat; - Regulate insulin sensitivity by the activation of peroxisome proliferator-activated receptor-γ - Pioglitazone group (58%) achieved primary outcome (NAS impovement ≥ 2 points without worsening of fibrosis) than patients in the placebo…”
BackgroundPosttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Self-citationHepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease
Jokinen, M. J., & Luukkonen, P. K. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.02.003 · Cited by 27
Current strategies for nonalcoholic fatty liver disease treatment (Review)
Sun, J., Jin, X., & Li, Y. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5412 · Cited by 29
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“Despite being able to improve steatohepatitis at the examination of histological samples of the liver, pioglitazone was not clearly proven to determine a regression of the fibrosis after long term treatment [222].”
Raschi, E., Mazzotti, A., Poluzzi, E., Ponti, F. D., & Marchesini, G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1531126 · Cited by 29
Berković, M. C., Virović-Jukić, L., Bilić-Čurčić, I., & Mrzljak, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2740 · Cited by 25
Efficacy and safety of drugs for nonalcoholic steatohepatitis
Shen, B., & Lu, L. (2021) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12967 · Cited by 24
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 31
Ndakotsu, A. K., & Vivekanandan, G. (2022) · Cureus · doi:10.7759/cureus.25380 · Cited by 28
“[29] Pioglitazone 45 mg 18 months 101 51 Improved Improved Present”
BackgroundAn, J., & Sohn, J. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0437 · Cited by 25
Emerging pharmacological treatment options for MAFLD
Rojas, Á., Lara, C., Múñoz‐Hernández, R., Gato, S., Ampuero, J., & Romero‐Gómez, M. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221142452 · Cited by 59
Nonalcoholic fatty liver disease from a primary care perspective
Clark, J. M., Cryer, D. R. H., Morton, M., & Shubrook, J. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15016 · Cited by 27
Mao, T., Sun, Y., Xu, X., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000234 · Cited by 27
“…Phase 4 ) [265] Lobeglitazone Phase 4 — — √ √ — — Lee et al [266] Pioglitazone Phase 4 NAFLD/NASH with T2D — √ √ √ — Aithal et al [267] Cusi et al [268] PXL065 Phase 2 NASH — — √ — Poxel Harrison et al [269] PPAR Ratziu et al [270] PPAR α / γ Saroglitazar Phase 2 NAFLD/NASH — √ √ — Zydus…”
Kanhai, A. A., Bange, H., Verburg, L., Dijkstra, K. L., Price, L., Peters, D. J. M., & Leonhard, W. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-58382-z · Cited by 26
Ivashkin, V. T., Drapkina, O. M., Maevskaya, M. V., Raikhelson, K. L., Okovityi, S. V., Жаркова, М. С., Grechishnikova, V. R., Abdulganieva, D. I., Alekseenko, S. A., Ardatskaya, M. D., et al. (2025) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2025-35-1-94-152 · Cited by 31
Goto, H., & Takamura, T. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25017 · Cited by 30
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
Colca, J. R., McDonald, W. G., McCommis, K. S., & Finck, B. N. (2017) · Hepatology Communications · doi:10.1002/hep4.1036 · Cited by 24
Ipsen, E. Ø., Madsen, K. S., Chi, Y., Pedersen-Bjergaard, U., Richter, B., Metzendorf, M.-I., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013516.pub2 · Cited by 23
Dalem, J. D. R.-V., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2021) · Hepatology · doi:10.1002/hep.32012 · Cited by 25
Adams, S. C., McMillan, J., Salline, K., Lavery, J. A., Moskowitz, C. S., Matsoukas, K., Chen, M. M. Z., Mina, D. S., Scott, J. M., & Jones, L. W. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-048218 · Cited by 27
Miao, L., Xu, J., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0015 · Cited by 27
Pennisi, G., Celsa, C., Enea, M., Vaccaro, M., Marco, V. D., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Vernuccio, F., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.07.001 · Cited by 24
Wang, S.-Q., Xiang, J. H., Zhang, G., Fu, L., Xu, Y., Chen, Y., Tao, L., Hu, X., & Shen, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155227 · Cited by 28
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 26
Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
Tomasiewicz, K., Flisiak, R., Halota, W., Jaroszewicz, J., Lebensztejn, D. M., Lisik, W., Małkowski, P., Pawłowska, M., Piekarska, A., Simon, K. A., et al. (2018) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2018.78118 · Cited by 26
The Future of Nonalcoholic Fatty Liver Disease Treatment
Mazhar, K. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.08.005 · Cited by 26
Povsic, M., Oliver, L., Jiandani, N. R., Perry, R., & Bottomley, J. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.485 · Cited by 23
Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
Yen, F., Yang, Y., Hwu, C., Wei, J. C., Huang, Y., Hou, M., & Hsu, C. (2020) · Liver International · doi:10.1111/liv.14385 · Cited by 25
Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?
Khandelwal, R., Dassanayake, A. S., Conjeevaram, H. S., & Singh, S. P. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1479 · Cited by 29
Review article: vascular effects of PPARs in the context of NASH
Guixé‐Muntet, S., Biquard, L., Szabó, G., Dufour, J., Tacke, F., Francque, S., Rautou, P., & Gracia‐Sancho, J. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17046 · Cited by 22
Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
Rabiu, L., Zhang, P., Afolabi, L. O., Saliu, M. A., Dabai, S. M., Suleiman, R. B., Gidado, K. I., Ige, M. A., Ibrahim, A., Zhang, G., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02157-0 · Cited by 26
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?
Soti, S., Corey, K. E., Lake, J. E., & Erlandson, K. M. (2018) · Current HIV/AIDS Reports · doi:10.1007/s11904-018-0392-1 · Cited by 23
Multi-drug approaches to NASH: what’s in the development pipeline?
Johnston, M. P., Patel, J., & Byrne, C. D. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1668926 · Cited by 22
Sridharan, K., Sivaramakrishnan, G., Sequeira, R. P., & Elamin, A. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-135967 · Cited by 24
TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse
Bernardi, S., Toffoli, B., Tisato, V., Bossi, F., Biffi, S., Lorenzon, A., Zauli, G., Secchiero, P., & Fabris, B. (2017) · Clinical Science · doi:10.1042/cs20171221 · Cited by 21
“Several 349 studies have shown that PPARγ agonists significantly reduce hepatic triglyceride content and NAFLD 350 in patients with diabetes (38, 39).”
BackgroundCherukuri, L., Smith, M. S., & Tayek, J. A. (2018) · doi:10.31038/edmj.2018232 · Cited by 21
Yap, C. H., Junit, S. M., Aziz, A. A., & Kong, K. W. (2019) · Food Bioscience · doi:10.1016/j.fbio.2019.100489 · Cited by 24
What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?
David, D., & Eapen, C. E. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.09.001 · Cited by 26
Yen, F., Hsu, C., Wei, J. C., Hou, M., & Hwu, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.839456 · Cited by 23
NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
Chen, B. Y., Tang, W. H. W., Rodriguez, M., Corey, K. E., Sanyal, A. J., Kamath, P. S., Bozkurt, B., Virk, H. U. H., Pressman, G. S., Lazarus, J. V., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1757712 · Cited by 24
PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?
Theys, C., Lauwers, D., Perez-Novo, C. A., & Berghe, W. V. (2022) · Biomedicines · doi:10.3390/biomedicines10123041 · Cited by 23
Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 26
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes
Cernea, S., Cahn, A., & Raz, I. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1300059 · Cited by 24
Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis
Lee, J. I., Lee, H. W., & Lee, K. S. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4959 · Cited by 25
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
A Novel 2-Hit Zebrafish Model to Study Early Pathogenesis of Non-Alcoholic Fatty Liver Disease
Kulkarni, A., Ibrahim‐Shaikh, S., Haider, I., Basha, A., Montgomery, E., Ermis, E., Mirmira, R. G., & Anderson, R. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020479 · Cited by 22
Metadata
- Authors
- Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., & Portillo-Sanchez, P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- From University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, and University of Texas Health Science Center at San Antonio and Audie L. Murphy Veterans Affairs Medical Center, San Antonio, Texas.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-09-06
- Volume
- 165
- Issue
- 5
- Pages
- 305-315
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2470709274
- Cited by
- 1,024
- References
- 62
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 109 · 2023: 103 · 2022: 116 · 2021: 131 · 2020: 108 · 2019: 85 · 2018: 85 · 2017: 67 · 2016: 27
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- U.S. Department of Veterans Affairs (1 I01 CX000167-01)
- American Diabetes Association
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, prediabetes, type 2 diabetes, long-term treatment, hypocaloric diet, NASH resolution, liver fibrosis, hepatic triglyceride content, insulin sensitivity, insulin resistance, PPARγ agonists, drug safety, adverse events, liver histopathology, hepatic steatosis
- MeSH terms
- Pioglitazone, Transaminases, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Prediabetic State, Triglycerides, Biomarkers, Weight Gain, Thiazolidinediones, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.